

Alphora Research Inc. Completes Cytotoxics Lab

Alphora is pleased to announce the completion of a cytotoxics R&D laboratory, as part of an on-going \$4 million capital program for 2011. This investment continues to reinforce Alphora's experience for developing High Potency API's and is being driven by growing client demand and a general industry trend for increased development in this area. The 2011 capital program also includes other additions to R&D, GMP Operations, Analytical Services and staffing; some of which have also been completed.

The laboratory is designed to handle high potency active pharmaceutical ingredients (HPAPI's) and class 4 compounds. It is equipped with three hard enclosure isolator units, pressure lock entryways and dedicated class HEPA filtered air handling systems.

Alphora's R&D has been expanded by 50%, increasing the overall company headcount to 95 employees, installed additional fume hoods for process chemistry development and a GC/MS instrument for further API characterization and control of Genotoxic Impurities (GTI's).

Significant progress has also been made towards other areas of the expansion plan, including constructing a fourth cGMP Kilo Lab, 10,000 square foot GMP warehouse and installing a new Enterprise Resource Planning (ERP) system. These activities are on track and expected to wrap-up in the fourth quarter.

The cGMP Kilo Lab will be equipped with a 60L Buchi glass lined cryogenic vessel and supporting equipment. The unit will have a dedicated HEPA filtered heating and ventilation system and pressure locks suitable for class 100,000 use.

The new 10,000 square foot warehouse and ERP system for inventory monitoring will provide greater control and flexibility to its operations and facilitate further expansion of a second Pilot Plant, which is planned for 2012.

These expansions represent a significant investment for Alphora and reinforce the company's capabilities in API Technology Development, ensuring its clients continue to receive "the right development at the right time" through phase appropriate solutions.

Alphora provides API technology development services to the Pharmaceutical and Biotechnology industry that include process chemistry, analytical services as well as cGMP scale-up capabilities.

Founded in 2003 by Dr. Jan Oudenes, Alphora Research works closely with its clients to deliver pre-clinical and clinical stage API, and has conducted validation efforts in advance of market launch. Alphora's FDA inspected operations total 45,000 sq. ft. and include synthetic laboratories, analytical laboratories, cGMP stability studies, GMP kilo laboratories and a GMP Pilot Plant.

For additional information on this news release or about Alphora, please contact:

Geoff Evans,
Vice President, Business Operations

OR

Matt Frizzle
Account Manager, Business Development

